What Is Vedolizumab? How This IBD Treatment Works

Vedolizumab is a biologic medication used to treat two forms of inflammatory bowel disease (IBD): ulcerative colitis and Crohn’s disease. Sold under the brand name Entyvio, it works differently from many other biologics by targeting the gut’s immune system specifically rather than suppressing immunity throughout the body. That gut-selective approach has made it a cornerstone treatment for moderate-to-severe IBD, and the research behind it reveals some interesting trade-offs worth understanding.

How Vedolizumab Works

Your immune system constantly sends white blood cells around the body to patrol for problems. In the gut, a specific homing system guides certain immune cells to the intestinal lining. Those cells carry a surface protein called α4β7 integrin, which acts like a molecular handshake partner for another protein, MAdCAM-1, found on blood vessel walls in the gut. When the two proteins lock together, immune cells cross from the bloodstream into the intestinal tissue.

In ulcerative colitis and Crohn’s disease, this process goes haywire. Too many immune cells flood the gut lining, causing chronic inflammation, ulcers, and tissue damage. Vedolizumab is an antibody that binds directly to α4β7 integrin on those circulating immune cells, blocking the handshake with MAdCAM-1 and preventing them from infiltrating the intestinal wall.¹ The result is a reduction in the immune-driven inflammation that drives IBD symptoms.

This is a meaningfully different strategy from older biologics like infliximab and adalimumab, which are anti-TNF drugs. Those work by neutralizing tumor necrosis factor (TNF), an inflammatory signaling molecule found throughout the body. Vedolizumab’s advantage is that it focuses on gut-homing immune cells specifically, leaving the broader immune system largely intact.²

What the Landmark Trials Showed

Vedolizumab earned its approval based primarily on two large phase III trials known as GEMINI 1 (for ulcerative colitis) and GEMINI 2 (for Crohn’s disease). In ulcerative colitis, roughly half of patients treated with vedolizumab had a clinical response at six weeks, compared with about a quarter on placebo. By one year, about 42–45% of patients staying on vedolizumab were in clinical remission, compared with roughly 16% of those switched to placebo.³

In Crohn’s disease the results were more modest, reflecting the fact that Crohn’s is generally harder to treat with any biologic. About 15% of vedolizumab patients achieved remission at six weeks, versus about 7% on placebo. At one year, around 36–39% of vedolizumab responders maintained remission, compared with about 22% on placebo.⁴ Those early remission numbers for Crohn’s look small, but the maintenance benefit for people who do respond is substantial, and the data were strong enough for both the FDA and the European Medicines Agency to grant approval for both conditions.⁵

Vedolizumab Versus Anti-TNF Therapy

The question patients and doctors often face is not “does vedolizumab work?” but “does it work better than the alternatives?” The VARSITY trial was the first head-to-head comparison of two biologics in ulcerative colitis, pitting vedolizumab against adalimumab. At one year, about 31% of vedolizumab patients were in clinical remission versus about 23% on adalimumab. Vedolizumab also showed better endoscopic improvement, meaning the actual lining of the colon looked healthier on examination.⁶ Follow-up analyses of that trial found higher rates of histologic remission with vedolizumab as well, meaning tissue samples showed less microscopic inflammation.⁷

A caveat: VARSITY tested adalimumab without a loading dose optimization that some experts now prefer, so the comparison has its limits. There is also no equivalent head-to-head trial for Crohn’s disease, where anti-TNF drugs may hold a relative edge in certain patients, particularly those with complex fistulizing disease. Still, for ulcerative colitis specifically, VARSITY is the strongest direct evidence clinicians have.

Does Previous Treatment Matter

Many patients arriving at vedolizumab have already tried and failed an anti-TNF biologic. That prior exposure does affect outcomes, though perhaps not as dramatically as you might expect. In the GEMINI trials, patients who had never used anti-TNF therapy responded better overall: about 53% achieved a clinical response at six weeks in ulcerative colitis, compared with roughly 39% among those who had previously failed anti-TNF treatment. By one year, remission rates were about 47% for anti-TNF-naive patients and about 36% for anti-TNF-experienced patients.⁸

Those numbers tell a hopeful story for people who feel they have run out of options. Even after anti-TNF failure, vedolizumab still works in a meaningful proportion of patients. A review of studies examining the “switch versus swap” question found that a considerable number of patients respond to vedolizumab even after primary failure of an anti-TNF agent, and whether the prior failure was primary (the drug never worked) or secondary (the drug stopped working over time) did not seem to make a large difference in vedolizumab outcomes.⁹ The implication for treatment sequencing is increasingly that using vedolizumab early, before anti-TNF failure, may give you a better shot at remission.

Safety Profile

The gut-selective mechanism has a real safety payoff. Across the original clinical trials, involving thousands of patients and nearly 5,000 person-years of exposure, no increased risk of any infection or serious infection was linked to vedolizumab use. Serious intestinal infections like C. difficile, sepsis, and tuberculosis were reported in well under 1% of patients. Fewer than 1% were diagnosed with a malignancy.¹⁰

Long-term observational data have reinforced this. A large prospective study comparing vedolizumab-treated patients with those on other biologics found essentially identical rates of serious and opportunistic infections between the two groups, and no meaningful difference in cancer risk.¹¹ Older patients seem to do at least as well: those aged 55 and above had the lowest rate of serious infections in age-stratified analyses of the trials.¹²

The Brain Infection Question

One safety concern followed vedolizumab from the start because of a related drug. Natalizumab, another integrin blocker, targets both α4β7 and α4β1 integrins. The α4β1 part is involved in immune surveillance in the brain, and blocking it was linked to progressive multifocal leukoencephalopathy (PML), a rare and devastating brain infection. Because vedolizumab also targets integrins, there was understandable worry. But vedolizumab binds only to α4β7 and does not interfere with α4β1. In a study of healthy volunteers, vedolizumab caused no significant changes in cerebrospinal fluid immune cell populations, which is the pathway through which natalizumab is thought to enable PML.¹³ And across all the clinical trial data, no cases of PML were observed.¹⁴

How Vedolizumab Is Given

Vedolizumab was originally available only as an intravenous infusion. The standard schedule involves infusions at weeks 0, 2, and 6 for induction, then every eight weeks for maintenance. Each infusion takes about 30 minutes, plus monitoring time afterward. A subcutaneous (self-injectable) formulation is now available, allowing patients to give themselves an injection every two weeks at home after initial intravenous induction doses.

Real-world studies of patients switching from intravenous to subcutaneous vedolizumab have found that the switch preserves effectiveness and safety, with high patient satisfaction and a low rate of discontinuation.¹⁵ Pharmacokinetic modeling shows that the average steady-state drug levels achieved by the subcutaneous every-two-weeks regimen are comparable to those from intravenous every-eight-weeks dosing.¹⁶ For many patients, the subcutaneous option is a meaningful quality-of-life improvement because it eliminates regular trips to an infusion center.

Drug Levels and Therapeutic Monitoring

As with many biologics, not everyone achieves the same drug levels, and research increasingly shows that higher vedolizumab trough concentrations (the lowest level between doses) predict better outcomes. In one study, patients who achieved combined endoscopic and clinical remission had markedly higher trough levels at six weeks and at week 22 than those who did not. A trough threshold around 22 µg/mL at week 6 predicted combined remission reasonably well.¹⁷ Another study found that higher trough levels from week 2 through week 22 were associated with mucosal healing and clinical response in both ulcerative colitis and Crohn’s disease.¹⁸

This matters in practice because if you are on vedolizumab and not responding as well as expected, your doctor may check your drug levels. Low trough levels could mean dose escalation (shorter intervals or higher doses) is worth trying before concluding the drug has failed. Therapeutic drug monitoring for vedolizumab is not yet as standardized as it is for some anti-TNF agents, but it is increasingly part of clinical decision-making.

Immunogenicity

Like all biologic drugs, vedolizumab can trigger the body to produce anti-drug antibodies. These antibodies can reduce the drug’s effectiveness and lower its levels in the blood. The good news is that immunogenicity rates with continuous vedolizumab treatment are quite low: only about 2–3% of continuously treated patients tested positive for anti-drug antibodies in the clinical trials.¹⁹ However, patients who stopped vedolizumab and later restarted it had considerably higher antibody rates, around 22%.²⁰ The practical lesson: staying on vedolizumab continuously, rather than stopping and restarting, helps keep immunogenicity low. During the induction phase, one study detected anti-vedolizumab antibodies in about 17% of patients, but this rate dropped to about 3% during maintenance, and the antibodies did not correlate with clinical outcomes in that cohort.²¹

Extraintestinal Manifestations

IBD is not just a gut disease. Many patients develop problems outside the intestines, including joint pain, skin conditions like erythema nodosum, and liver disease like primary sclerosing cholangitis (PSC). Because vedolizumab’s mechanism is gut-selective, there has been legitimate uncertainty about whether it helps these extraintestinal manifestations (EIMs).

The evidence so far is mixed. Vedolizumab appears to help EIMs that track closely with gut inflammation, such as certain types of peripheral arthritis and skin lesions. However, it has not shown biochemical improvement in PSC.²² A systematic review and meta-analysis comparing vedolizumab and ustekinumab found that improvement of existing joint manifestations was somewhat better with ustekinumab (about 54% improved) compared with vedolizumab (about 42%), and worsening of joint symptoms was more common with vedolizumab.²³ A retrospective study, however, found that overall EIM clinical response at one year was comparable between the two drugs, at about 34% for vedolizumab and 36% for ustekinumab.²⁴

If you have significant joint symptoms alongside your IBD, this is a conversation worth having with your gastroenterologist. Vedolizumab may still control the gut disease well, but a systemic biologic like ustekinumab or an anti-TNF agent might better address both the bowel and joint problems simultaneously.

Pregnancy and Breastfeeding

Active IBD during pregnancy carries real risks, including preterm birth and low birth weight, so staying in remission matters. Vedolizumab crosses the placenta, but less so than some other biologics. In pharmacokinetic studies, vedolizumab levels in cord blood were lower than maternal blood levels in most cases, with a median infant-to-maternal ratio of about 0.59–0.66.²⁵ For comparison, anti-TNF drugs and ustekinumab tend to have infant-to-maternal ratios above 1, meaning the baby ends up with higher drug levels than the mother.²⁶

Case reports and growing prospective data suggest that continuing vedolizumab during pregnancy and breastfeeding has a safety profile similar to anti-TNF therapy, with no signal of increased adverse events for mothers or infants.²⁷ The lower placental transfer is theoretically reassuring, since the drug’s gut-selective mechanism means the infant’s developing immune system is less exposed. That said, the total body of evidence is still smaller than what exists for anti-TNF drugs in pregnancy, so decisions should be individualized with a specialist.

Vedolizumab in Children

Vedolizumab is not yet formally approved for pediatric patients, but it is frequently used off-label in children who have failed anti-TNF biologics. The VEDOKIDS study, a prospective multicenter cohort, provides the most robust data available. At 14 weeks, about 42% of children with ulcerative colitis and about 32% with Crohn’s disease achieved steroid-free remission.²⁸ By week 54, about 47% of children with ulcerative colitis and 25% with Crohn’s disease were in complete remission. Adverse events were mild, with headache, muscle aches, and fever being the most common, and none were classified as serious.²⁹ As with adults, ulcerative colitis responded better than Crohn’s disease.

Histologic Healing and Quality of Life

Clinicians increasingly look beyond symptom control and even beyond how the colon looks on camera. Histologic healing, where biopsy samples show a return to normal tissue architecture, represents a deeper level of disease control. Among vedolizumab-treated patients who achieved endoscopic healing, about 55% also had histologic healing on biopsy.³⁰ That figure is not universal, but it reflects that vedolizumab can drive genuinely deep tissue recovery in a substantial fraction of patients.

Quality-of-life improvements parallel the clinical response. In a UK and Ireland observational study, vedolizumab-treated patients saw meaningful improvements in work productivity and daily activity impairment by week 14, and these gains were generally sustained through one year.³¹ A separate study tracking health-related quality of life and fatigue found that patients who achieved steroid-free clinical remission improved significantly in symptom burden, daily function, and worry scores as early as two weeks, with improvements stabilizing by week 14 and holding steady for a year. Fatigue, one of the most disabling but least-discussed symptoms of IBD, dropped to background levels over six months in patients who reached remission.³² One intriguing finding from that study: quality-of-life improvements often appeared before formal clinical remission was documented, suggesting patients feel better before their lab values and endoscopy scores fully catch up.

How Long Patients Stay on Vedolizumab

Real-world persistence data give a more grounded view than clinical trials, because they capture the messy reality of varied patient populations, insurance complications, and side effects that lead people to stop treatment. In a multicenter study of ulcerative colitis patients, about 65% were still on vedolizumab at one year. Among those who initially achieved clinical remission, roughly 13% later discontinued because they lost their response.³³ Patients with shorter disease duration before starting vedolizumab fared better, reinforcing the idea that earlier use tends to yield better results.

Longer-term data from another cohort, followed for a median of about 28 months, found that about 54% of ulcerative colitis patients remained on vedolizumab at the end of follow-up. The median time to discontinuation among those who stopped was about 14 months. Prior use of other advanced therapies, steroid dependence at baseline, and more extensive disease all predicted worse persistence.³⁴ These are not discouraging numbers in context. Biologic persistence rates across all IBD therapies follow a similar pattern of gradual attrition, and vedolizumab’s safety profile means that for patients who do maintain response, staying on it long-term carries relatively low risk.

Cost Considerations

Biologics are expensive, and vedolizumab is no exception. Economic modeling from the UK found that for patients who had never used anti-TNF therapy, vedolizumab was cost-effective compared with adalimumab and actually dominated (meaning it was both cheaper and more effective than) infliximab and golimumab in that modeling framework.³⁵ A Polish analysis found that infliximab and vedolizumab had the most favorable cost-effectiveness profiles among anti-TNF-naive patients, though results shifted in anti-TNF-experienced populations where newer agents like tofacitinib became more competitive.³⁶ These analyses are highly sensitive to local drug pricing, so the economics look different in every country. The availability of the subcutaneous formulation has also shifted costs downward in some settings by eliminating infusion-center overhead.